Zhang Guojun, Yang Chuan, Zhao Caixia, Xian Feng, Qing Dong, Guo Qiyu, Song Junmei, Liu Xilin, Bie Jun
Department of Oncology, Nanchong Central Hospital and The Second Clinical Medical College of North Sichuan Medical College, Nanchong, People's Republic of China.
Department of Oncology, Guangyuan Central Hospital, Guangyuan, People's Republic of China.
Cancer Manag Res. 2023 Jan 30;15:101-112. doi: 10.2147/CMAR.S395191. eCollection 2023.
The neutrophil-to-lymphocyte ratio (NLR) has been shown to have prognostic value in several common cancers. This study aimed to investigate the prognostic value of NLR in patients with advanced oesophageal squamous cell carcinoma (ESCC) after definitive chemoradiotherapy (dCRT).
A retrospective analysis was performed on 158 patients with advanced ESCC who received dCRT from January 2012 to December 2018. The NLR for different treatment stages was calculated based on laboratory test results. The Kaplan-Meier (KM) method and Cox proportional regression model were used to analyse the relationship between NLR and overall survival (OS).
The mean NLR of 158 patients with ESCC was 3.403 ± 2.479. The pre-treatment NLR cut-off was 4.839, and patients were divided into the low NLR group (NLR < 4.839) and the high NLR group (NLR ≥ 4.839). NLR in patients with ESCC was related to N stage (P < 0.05). The KM analysis showed that the median OS of all enrolled patients was 29.3 months, the median OS periods of patients in the high and low NLR groups were 15.6 and 35.8 months, respectively, and the OS of the low NLR group was better than that of the high NLR group (P < 0.001). In the multivariate analysis, NLR was an independent prognostic factor that affects the prognosis of patients with ESCC receiving dCRT. Furthermore, patients who maintained a high NLR before and after treatment showed worse clinical outcomes than the other groups.
Our findings suggest that NLR can effectively assess the prognosis of patients with advanced ESCC undergoing dCRT.
中性粒细胞与淋巴细胞比值(NLR)已被证明在几种常见癌症中具有预后价值。本研究旨在探讨NLR在接受根治性放化疗(dCRT)的晚期食管鳞状细胞癌(ESCC)患者中的预后价值。
对2012年1月至2018年12月期间接受dCRT的158例晚期ESCC患者进行回顾性分析。根据实验室检查结果计算不同治疗阶段的NLR。采用Kaplan-Meier(KM)法和Cox比例回归模型分析NLR与总生存期(OS)之间的关系。
158例ESCC患者的平均NLR为3.403±2.479。治疗前NLR临界值为4.839,患者分为低NLR组(NLR<4.839)和高NLR组(NLR≥4.839)。ESCC患者的NLR与N分期相关(P<0.05)。KM分析显示,所有入组患者的中位OS为29.3个月,高NLR组和低NLR组患者的中位OS期分别为15.6个月和35.8个月,低NLR组的OS优于高NLR组(P<0.001)。在多因素分析中,NLR是影响接受dCRT的ESCC患者预后的独立预后因素。此外,治疗前后维持高NLR的患者临床结局比其他组更差。
我们的研究结果表明,NLR可以有效评估接受dCRT的晚期ESCC患者的预后。